Université Paris-Sud (FR)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
75
Publications
1116
Citations
51801
i10-index
310
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
TGFβ attenuates tumour response to PD-L1 blockade ... | 2018 | 5078 |
Gut microbiome influences efficacy of PD-1–based i... | 2017 | 4991 |
Abiraterone and Increased Survival in Metastatic P... | 2011 | 4321 |
Atezolizumab in patients with locally advanced and... | 2016 | 3638 |
Enzalutamide in Metastatic Prostate Cancer before ... | 2014 | 2951 |
MPDL3280A (anti-PD-L1) treatment leads to clinical... | 2014 | 2392 |
Atezolizumab as first-line treatment in cisplatin-... | 2016 | 2143 |
Avelumab Maintenance Therapy for Advanced or Metas... | 2020 | 1374 |
Atezolizumab versus chemotherapy in patients with ... | 2017 | 1369 |
Erdafitinib in Locally Advanced or Metastatic Urot... | 2019 | 1277 |
Yohann Loriot is a researcher with 1116 publications and 51801 citations. They are affiliated with Université Paris-Sud. Their research focuses on . With an h-index of 75, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Yohann Loriot and 250M+ other papers.
Citations per publication by year